Durvalumab + Tremelimumab

Treatment for Mesothelioma

Typical Dosage: Tremelimumab 1mg/kg D1 (x4) + Durvalumab 1500mg Q3W (x4), then Durvalumab 1500mg Q4W

Effectiveness
72%
Safety Score
35%
Clinical Trials
6
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
MethπŸ’€
Cigarettes🚬
Chemo☒️
Alcohol🍺
MorphineπŸ’Š
AntibioticsπŸ’‰
TylenolπŸ’Š
ExerciseπŸƒ
WaterπŸ’§
35
DangerousModerateSafe
Treatment Details
Dosage Range
Tremelimumab 1mg/kg D1 (x4) + Durvalumab 1500mg Q3W (x4), then Durvalumab 1500mg Q4W
Time to Effect
2-4 months
Treatment Duration
Up to 2 years for Durvalumab, Tremelimumab 4 doses
Evidence Quality
HIGH
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$260,000
Monitoring:$12,000
Side Effect Mgmt:$15,000
Total Annual:$287,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$130,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$820,000
Cost per Remission
$5,740,000
Comparison vs Pemetrexed + Cisplatin
Cost Difference
+$267,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Durvalumab + Tremelimumab Outcomes

for Mesothelioma

Efficacy Outcomes
Overall Effectiveness
+72%
Response Rate
+35%
Remission Rate
+5%
Common Side Effects
Diarrhea
+30%
Fatigue
+35%
Nausea
+20%
Rash
+20%
Hepatitis
+7%
Colitis
+6%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
1 active trial recruiting for Durvalumab + Tremelimumab in Mesothelioma

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

NCT05932199RECRUITINGPHASE1, PHASE2
View Study
52 participants
INTERVENTIONAL
Durham, United States +1 more
Started: Jul 3, 2024
Completed Clinical Trials
3 completed trials for Durvalumab + Tremelimumab in Mesothelioma

......SMARTEST Trial......

NCT05380713COMPLETEDPHASE2
View Study
30 participants
INTERVENTIONAL
Toronto, Canada
Started: May 3, 2022

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

NCT02592551COMPLETEDPHASE2
View Study
24 participants
INTERVENTIONAL
Houston, United States
Started: May 11, 2016

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

NCT02141347COMPLETEDPHASE1
View Study
65 participants
INTERVENTIONAL
Bunkyō City, Japan +10 more
Started: May 22, 2014